
    
The genomic variant c.35G>T p.Gly12Val, also known as rs121913529, is a missense mutation located in the KRAS gene, which encodes the KRAS protein, a member of the RAS family of GTPases. This protein plays a critical role in regulating cell division, cell differentiation, and cell death through signal transduction pathways. The KRAS gene is a proto-oncogene, and its product is involved in the RAS/MAPK signaling pathway, which is essential for the control of several cellular processes including proliferation, survival, and metabolism.The c.35G>T p.Gly12Val mutation results in the substitution of a glycine (Gly) with a valine (Val) at the 12th amino acid position of the KRAS protein. This alteration is located in a region critical for the GTPase activity of the protein, which is responsible for cycling between active (GTP-bound) and inactive (GDP-bound) states. The Gly12Val mutation impairs the intrinsic GTPase activity of KRAS, leading to an accumulation of the GTP-bound form, which constitutively activates downstream signaling pathways and promotes oncogenesis [1].KRAS mutations, including the Gly12Val variant, are associated with a variety of cancers, with the KRAS gene being one of the most frequently mutated in human tumors. The G12D mutation, which is similar to the Gly12Val mutation, has been extensively studied and is known to disrupt the interaction between KRAS and GTPase-activating proteins (GAPs), preventing the hydrolysis of GTP to GDP and leading to uncontrolled cell proliferation [1]. Although the Gly12Val mutation is less common than G12D, it is presumed to have a similar impact on KRAS function and oncogenic potential.The presence of KRAS mutations, including Gly12Val, has been investigated in the context of lung adenocarcinoma, where it was found to be more frequent in males and former/current smokers. The mutation was also associated with specific clinicopathologic features and co-occurring genomic alterations, such as TP53 and STK11 mutations [2]. In the context of pancreatic ductal adenocarcinoma (PDAC), KRAS mutations are particularly prevalent and have been the focus of drug development efforts due to the poor prognosis associated with these tumors [3].Efforts to target KRAS mutations therapeutically have led to the development of inhibitors, such as sotorasib and adagrasib, which are FDA-approved for treating lung cancers with the G12C mutation. However, inhibitors for the Gly12Val mutation are still under investigation, with recent studies exploring non-covalent inhibitors and machine learning algorithms to identify potential drug candidates [3][5].Additionally, deep mutational scanning has been used to explore the functional impact of various KRAS mutations, including the Gly12Val variant, providing insights into the mechanisms of KRAS-mediated oncogenesis and potential avenues for therapeutic intervention [4].In summary, the KRAS c.35G>T p.Gly12Val rs121913529 variant is a pathogenic missense mutation that alters the function of the KRAS protein, leading to constitutive activation of oncogenic signaling pathways. This mutation is implicated in the development of various cancers and is the subject of ongoing research to develop targeted therapies. With 41 pathogenic submissions in ClinVar, the significance of this variant in oncology is well recognized.

ゲノム変異c.35G>T p.Gly12Val（rs121913529としても知られる）は、KRAS遺伝子に位置するミスセンス変異です。この遺伝子はRASファミリーのGTPアーゼの一員であるKRASタンパク質をコードしています。このタンパク質は、細胞分裂、細胞分化、細胞死をシグナル伝達経路を通じて調節する上で重要な役割を果たします。KRAS遺伝子はプロトオンコジーンであり、その産物はRAS/MAPKシグナル伝達経路に関与しており、この経路は増殖、生存、代謝を含むいくつかの細胞プロセスの制御に不可欠です。

c.35G>T p.Gly12Val変異は、KRASタンパク質の12番目のアミノ酸位置でグリシン（Gly）がバリン（Val）に置換される結果をもたらします。この変化は、タンパク質のGTPアーゼ活性に重要な領域に位置しており、GTP結合型の活性状態とGDP結合型の不活性状態の間を循環する能力を担っています。Gly12Val変異はKRASの内因性GTPアーゼ活性を損なうため、GTP結合型の形態が蓄積し、下流のシグナル伝達経路が恒常的に活性化され、腫瘍形成（発がん）を促進します[1]。

KRAS変異（Gly12Val変異を含む）は、さまざまな癌と関連しており、KRAS遺伝子はヒト腫瘍で最も頻繁に変異する遺伝子の1つです。Gly12Val変異に類似したG12D変異は広く研究されており、KRASとGTPアーゼ活性化タンパク質（GAPs）との相互作用を妨げ、GTPがGDPに加水分解されるのを防ぎ、制御不能な細胞増殖を引き起こすことが知られています[1]。Gly12Val変異はG12Dほど一般的ではありませんが、KRASの機能と発がん性に類似した影響を与えると推定されています。

KRAS変異（Gly12Valを含む）の存在は、肺腺癌の文脈で調査されており、男性および元喫煙者/現在の喫煙者でより頻繁に見られることが判明しました。この変異は、特定の臨床病理学的特徴やTP53およびSTK11変異などの共存するゲノム変化とも関連していました[2]。膵管腺癌（PDAC）の文脈では、KRAS変異は特に多く見られ、これらの腫瘍に関連する予後不良のため、薬剤開発の焦点となっています[3]。

KRAS変異を標的とする治療法の開発努力により、G12C変異を有する肺癌の治療にFDAが承認したソトラシブやアダグラシブなどの阻害剤が開発されました。しかし、Gly12Val変異に対する阻害剤はまだ研究段階にあり、最近の研究では非共有結合型阻害剤や機械学習アルゴリズムを用いて潜在的な薬剤候補を特定する試みが行われています[3][5]。

さらに、深部変異スキャニングが、Gly12Val変異を含むさまざまなKRAS変異の機能的影響を探るために使用されており、KRASを介した発がんのメカニズムや治療介入の可能性についての洞察を提供しています[4]。

まとめると、KRAS c.35G>T p.Gly12Val rs121913529変異は、KRASタンパク質の機能を変化させ、発がん性シグナル伝達経路を恒常的に活性化させる病原性のミスセンス変異です。この変異はさまざまな癌の発症に関与しており、標的治療法の開発に向けた研究が進行中です。ClinVarにおける41件の病原性提出が示すように、この変異の腫瘍学における重要性は広く認識されています。
    
## References
- [1] Randelovic I et al. (2024). "Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development." International journal of molecular sciences, 25(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38473821/)
- [2] Cao H et al. (2024). "Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma." European journal of cancer (Oxford, England : 1990), 202() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38452722/)
- [3] Ajmal A et al. (2024). "In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches." Pharmaceuticals (Basel, Switzerland), 17(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38794122/)
- [4] Kwon JJ et al. (2024). "Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity." bioRxiv : the preprint server for biology, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/39484452/)
- [5] Park SY et al. (2024). "Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy." Heliyon, 10(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38617914/)
- [6] Hamidi Sofiani V et al. (2024). "Association of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues." The Journal of international medical research, 52(12) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39673361/)
- [7] Zhou C et al. (2024). "Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer." Cancer cell, 42(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38942026/)
- [8] Zhou C et al. (2024). "Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS(G12D)." Journal of medicinal chemistry, 67(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38197882/)
- [9] Liu S et al. (2024). "KRAS Mutation Detection with (2S,4R)-4-[(18)F]FGln for Noninvasive PDAC Diagnosis." Molecular pharmaceutics, 21(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38456403/)
- [10] Sun R et al. (2024). "Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors." Bioorganic chemistry, 148() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38781668/)
- [11] Tu G et al. (2024). "Pathways and mechanism of MRTX1133 binding to KRAS G12D elucidated by molecular dynamics simulations and Markov state models." International journal of biological macromolecules, 274(Pt 2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38925182/)
- [12] Tajiknia V et al. (2024). "Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation." American journal of cancer research, 14(9) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39417197/)
- [13] Zhu H et al. (2024). "Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15." Nature communications, 15(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38402201/)
- [14] Trinh VQ et al. (2025). "Mutant GNAS drives a pyloric metaplasia with tumor suppressive glycans in intraductal papillary mucinous neoplasia." bioRxiv : the preprint server for biology, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/38464029/)
- [15] Zheng W et al. (2024). "Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development." Oncology research, 32(12) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39574477/)

    
## ClinVar Submissions
- **[RCV000029215](https://www.ncbi.nlm.nih.gov/clinvar/RCV000029215/)**: Linear nevus sebaceous syndrome
- **[RCV000157944](https://www.ncbi.nlm.nih.gov/clinvar/RCV000157944/)**: not provided
- **[RCV000272938](https://www.ncbi.nlm.nih.gov/clinvar/RCV000272938/)**: not provided
- **[RCV000548006](https://www.ncbi.nlm.nih.gov/clinvar/RCV000548006/)**: RASopathy
- **[RCV000150895](https://www.ncbi.nlm.nih.gov/clinvar/RCV000150895/)**: Juvenile myelomonocytic leukemia
- **[RCV000154262](https://www.ncbi.nlm.nih.gov/clinvar/RCV000154262/)**: Non-small cell lung carcinoma
- **[RCV000585796](https://www.ncbi.nlm.nih.gov/clinvar/RCV000585796/)**: Cerebral arteriovenous malformation
- **[RCV003455987](https://www.ncbi.nlm.nih.gov/clinvar/RCV003455987/)**: Linear nevus sebaceous syndrome
- **[RCV003539760](https://www.ncbi.nlm.nih.gov/clinvar/RCV003539760/)**: RASopathy
- **[RCV000013411](https://www.ncbi.nlm.nih.gov/clinvar/RCV000013411/)**: Carcinoma of pancreas
- **[RCV000013413](https://www.ncbi.nlm.nih.gov/clinvar/RCV000013413/)**: Carcinoma of pancreas
- **[RCV000022799](https://www.ncbi.nlm.nih.gov/clinvar/RCV000022799/)**: Epidermal nevus
- **[RCV000029214](https://www.ncbi.nlm.nih.gov/clinvar/RCV000029214/)**: Nevus sebaceous
- **[RCV000029216](https://www.ncbi.nlm.nih.gov/clinvar/RCV000029216/)**: Nevus sebaceous
- **[RCV000038266](https://www.ncbi.nlm.nih.gov/clinvar/RCV000038266/)**: Non-small cell lung carcinoma

    